Search clinical trials for: ibrutinib and Tisagenlecleucel

Total 270808 results

Novartis Pharmaceuticals

Terminated

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Diffuse Large B-cell Lymphoma

United States
Peter MacCallum Cancer Centre, Australia
Novartis

Active, not recruiting

Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Mantle Cell Lymphoma Recurrent

Australia
Novartis Pharmaceuticals

Recruiting

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Diffuse Large B-cell Lymphoma

Brazil
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
Novartis Pharmaceuticals

Completed

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

Diffuse Large B-cell Lymphoma

United States
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA)

Follicular Lymphoma

United States, Spain, Belgium, Japan, Australia, Germany, Italy, Netherlands, Norway, United Kingdom, Austria, France
Novartis Pharmaceuticals

Withdrawn

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL)
Novartis Pharmaceuticals

Available

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Acute Lymphoblastic Leukemia (ALL) | Diffuse Large B-cell Lymphoma (DLBCL)

United States, Canada, Australia
Novartis Pharmaceuticals

Withdrawn

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

B-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)

B-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults

Healthy

Belgium
TG Therapeutics, Inc.

Completed

Ublituximab + Ibrutinib in Select B-cell Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia

United States
Oncternal Therapeutics, Inc
University of California, San Diego; Pharmacyclics LLC.; California Institute...

Active, not recruiting

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Johnson & Johnson Private Limited

Completed

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

India
Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Healthy

United States
Stanford University

Not yet recruiting

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Leukemia | Acute Lymphoblastic Leukemia

United States
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Recruiting

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

B-cell Acute Lymphoblastic Leukemia

United States
Matthew J. Frigault, M.D.
Novartis

Active, not recruiting

Tisagenlecleucel In Primary CNS Lymphoma

Primary CNS Lymphoma | Refractory Primary CNS Lymphoma | Relapsed Primary CNS Lymphoma

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ELIANA)

B-cell Acute Lymphoblastic Leukemia

United States, Belgium, Germany, Austria, Canada, Italy, Japan, Norway, Australia, France, Spain
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson

Enrolling by invitation

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host Disease

United States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
Janssen-Cilag Ltd.

Completed

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (FIRE)

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

France
The Lymphoma Academic Research Organisation

Completed

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

Intraocular Lymphoma | Primary Central Nervous Lymphoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

Chronic Lymphocytic Leukemia

Italy
Janssen-Cilag S.p.A.

Completed

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting (EVIdeNCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Italy
The First Affiliated Hospital with Nanjing Medical...
Xian-Janssen Pharmaceutical Ltd.

Unknown

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease

Chronic Graft-versus-host-disease

Mexico
IRCCS San Raffaele

Recruiting

Real World Data on Ibrutinib Use in PCNSL Rel/Ref (ReWIPretro)

PCNSL

Italy
Memorial Sloan Kettering Cancer Center
Ohio State University; Pharmacyclics LLC.; Janssen Biotech, Inc.

Completed

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

T-cell Lymphoma | Relapsed and Refractory T-cell Lymphoma

United States
University of Cologne

Completed

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) (IRENO)

Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Germany
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; Pharmacyclics LLC.

Terminated

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Follicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIa

United States
Janssen Biotech, Inc.
Pharmacyclics LLC.

Approved for marketing

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

United States, Brazil, Puerto Rico
Peking University People's Hospital
Beijing Hospital

Unknown

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Leukemia, Lymphocytic, Chronic, B-Cell
Novartis Pharmaceuticals

Recruiting

Study of Out of Specification for Tisagenlecleucel

Diffuse Large B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

Japan, Canada
Novartis Pharmaceuticals
Children's Oncology Group

Recruiting

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)

B-Cell Acute Lymphoblastic Leukemia

United States, Belgium, Italy, Sweden, Netherlands, Norway, United Kingdom, Germany, Canada, Spain, France, Finland, Denmark
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals

Completed

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
University of Michigan Rogel Cancer Center

Withdrawn

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Healthy

United States
US Oncology Research
AbbVie; Pharmacyclics LLC.

Active, not recruiting

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Breast Neoplasms | Malignant Neoplasm of Breast

United States
The University of Hong Kong
Janssen, LP

Unknown

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Follicular Lymphoma | Chronic Hepatitis B | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Indolent B-cell Lymphomas | Waldenstrom's Macroglobulinaemia

Hong Kong
Janssen Research & Development, LLC

Withdrawn

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell
Jeanette Lundin

Recruiting

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) (IbruOnOff)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Sweden, Norway
Memorial Sloan Kettering Cancer Center
Bayer

Completed

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

United States
Johnson & Johnson Private Limited

Completed

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

India
Ann & Robert H Lurie Children's Hospital of Chicago
Northwestern University Feinberg School of Medicine

Completed

Inhibition of Anaphylaxis by Ibrutinib

Food Allergy | Anaphylaxis Food

United States
National Cancer Institute (NCI)

Recruiting

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Chronic GVHD

United States
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan

Search clinical trials for: ibrutinib and Tisagenlecleucel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations